Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isola
about
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing EnterobacteriaceaeDiversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study.The inoculum effect of antibiotics against CTX-M-extended-spectrum β-lactamase-producing Escherichia coli.In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremiaMechanisms of antimicrobial resistance in Gram-negative bacilli.Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceaeβ-lactam/β-lactamase inhibitor combinations: from then to now.The complex epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae.The challenge of antibiotic resistance in haematology patients.Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Direct disk diffusion test using European Clinical Antimicrobial Susceptibility Testing breakpoints provides reliable results compared with the standard method.Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.Unmet needs in the management of intra-abdominal infections.Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae.Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations.International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.Noncarbapenem ß-Lactams for the Treatment of Extended-Spectrum ß-Lactamase Infections: What Are the Remaining Drugs Outside the United States?β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.Antibiotic stewardship program in Intensive Care Unit: First report from Iran.
P2860
Q28551534-55267397-7906-4215-975B-BAD306C1A770Q30389929-2DD01DB2-A260-4E81-889F-5BFDB27DD755Q35158603-14B08307-47BB-4A5D-804A-8FA03B58F234Q35666617-75AB5360-99F8-438D-BD32-A8849CDA06DEQ35715650-675D71B5-F7F7-41DA-A821-4380388EA636Q35935319-5AE6B2AC-9313-4850-80F0-00F4A2B6AD40Q36730017-44E2E029-4022-41B1-AB67-E098D56FDC02Q36785886-A4A04624-C6E0-4294-82FC-559B8590DD42Q37023191-99584921-5A3A-403F-ACB8-EA90A778342AQ38264182-58D55DCF-5FA8-4E94-9B96-3D279B61BEFFQ38497797-42ABB5ED-F0FA-46EF-A93E-D3EDA4E4E611Q38613929-051D7F02-48DC-4040-A412-E28C295AF121Q38681779-F9C4EE04-A3CF-4006-9C9B-FDB5D2579B7BQ38792841-8ADEDAAF-253A-41AF-B4D1-85341B83ACFFQ38864569-16ADAFA2-990B-4866-B6AA-A1CB2DF191D2Q38981397-C2DD535E-194D-4258-AECE-9B04F173ADDEQ39656197-1F8FF7C7-FC3B-41EA-B41A-F2949A3865C5Q40044307-27F57B2C-4CA7-4AE7-B684-587DD9FF032BQ40079705-AB10ADAE-A732-4544-8749-92E606F453ACQ41004466-B700B6D9-8706-4FF6-8326-ECE8B7566CE8Q42738176-0B91C869-3566-4B60-9AF5-70236A1877D8Q44720612-85A6FD3F-16BE-45B3-8735-11D4501F2110Q47312597-4DF0460D-8AC1-4A74-94C7-7590D01E7D10Q50094170-C4F02B9D-727D-4105-851F-A50A373FE5ABQ50523195-D1DB1648-032E-4513-95A5-3F2204581CA7Q52695014-A935CC0D-6CD6-4128-91B6-34130D14D1EEQ55512039-DE3012E8-3B57-4C33-AF3D-04B85F12D664
P2860
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isola
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Comparative assessment of inoc ...... oducing Escherichia coli isola
@en
Comparative assessment of inoc ...... oducing Escherichia coli isola
@nl
type
label
Comparative assessment of inoc ...... oducing Escherichia coli isola
@en
Comparative assessment of inoc ...... oducing Escherichia coli isola
@nl
prefLabel
Comparative assessment of inoc ...... oducing Escherichia coli isola
@en
Comparative assessment of inoc ...... oducing Escherichia coli isola
@nl
P2093
P50
P1476
Comparative assessment of inoc ...... cing Escherichia coli isolates
@en
P2093
P304
P356
10.1111/J.1469-0691.2009.02893.X
P577
2009-07-15T00:00:00Z